Back to results
US 9,175,347 B2Granted
Genomic markers for prediction of long-term response to growth hormone (GH) therapy
AssigneeMerck Serono SA
InventorsPascal Croteau, John Raelson, Jerome Wojcik, Benoît Destenaves, Clement Olivier, Sonia Schnieper-Samec
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
Claims2
A method of treating Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) in an individual in need thereof, the method comprising the steps of:
- a) determining in a DNA sample of the individual whether in GRB10 rs933360 either of the TT, CC or TC genotype is present;
- b) predicting from the presence of the CC or TC genotype in GRB10 rs933360 an intermediate or low change in height in cm from baseline or predicting from the presence of the TT genotype in GRB10 rs933360 a high change in height in cm from baseline;
- and
- c) administering a standard dose of growth hormone to an individual having the TT genotype in GRB10 rs933360, or administering an increased dose of growth hormone, as compared to a standard dose, or a long acting analog of growth hormone to an individual having in GRB10 rs933360 either the CC or TC genotype.
1 more element
A method of treating Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) in an individual in need thereof, the method comprising the steps of:
- a) administering growth hormone to said individual for a period of one year;
- b) determining in a DNA sample of the individual whether in GRB10 rs933360 the TT, CC, or TC genotype is present;
- c) predicting from the presence of the TT, CC, or TC genotype in GRB10 rs933360 a high, intermediate or low change in height in cm from baseline;
- and
- d) administering a standard dose of growth hormone to an individual having the TT genotype in GRB10 rs933360, or administering an increased dose of growth hormone, as compared to a standard dose, or a long acting analog of growth hormone to an individual having in GRB10 rs933360 either the CC or TC genotype.
2 more elements
Dependencies are inferred from the claim text.